Benzinga · Sep 9, 2026
This Illumina Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
Analysts upgraded Sagimet, Figure, Illumina, Martin Marietta and Waters, raising price targets and improving ratings.
SG
NASDAQ · SGMT
Sagimet Biosciences Inc.
Healthcare · Biotechnology
$10.46
Up+$0.71 (+6.79%)
Updated Sep 17, 2026, 8:59 PM
SID Score
5.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 196.86M
- P/E ratio
- -3.57
- Dividend yield
- 0.00%
- 52-week range
- $4.50 – $11.45
- Volume
- 620.56K
- Avg. volume
- 561.82K
Price performance
SGMT price history
1M range · 20 trading sessions · Daily adjusted prices
SGMT closed at $10.46 after 20 trading sessions, down 1.13% for the selected period.
- Last close
- $10.46
- Period change
- -1.13%
- Period low
- $10.18
- Period high
- $11.06
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $10.51 | $10.62 | $10.25 | $10.46 | 620.56K |
| Sep 15, 2026 | $10.805 | $10.84 | $10.31 | $10.46 | 852.73K |
| Sep 14, 2026 | $10.96 | $11.095 | $10.82 | $10.88 | 516.76K |
| Sep 11, 2026 | $11.33 | $11.35 | $10.77 | $10.88 | 639.39K |
| Sep 10, 2026 | $10.75 | $11.449 | $10.67 | $11.06 | 937.7K |
| Sep 9, 2026 | $11.25 | $11.27 | $10.685 | $10.86 | 1.25M |
| Sep 8, 2026 | $10.84 | $11.17 | $10.65 | $10.71 | 805.61K |
| Sep 4, 2026 | $10.79 | $10.98 | $10.53 | $10.94 | 1.25M |
| Sep 3, 2026 | $11.205 | $11.24 | $10.62 | $10.92 | 1.14M |
| Sep 2, 2026 | $10.51 | $11.06 | $10.51 | $10.99 | 1.8M |
| Sep 1, 2026 | $10.15 | $10.72 | $10.15 | $10.50 | 752.2K |
| Aug 31, 2026 | $10.36 | $10.435 | $10.21 | $10.26 | 688.44K |
| Aug 28, 2026 | $10.62 | $10.81 | $10.47 | $10.55 | 574K |
| Aug 27, 2026 | $10.90 | $10.95 | $10.54 | $10.75 | 657.68K |
| Aug 26, 2026 | $10.26 | $10.87 | $10.105 | $10.86 | 1.24M |
| Aug 25, 2026 | $10.38 | $10.60 | $10.20 | $10.29 | 968.56K |
| Aug 24, 2026 | $10.13 | $10.505 | $9.95 | $10.21 | 1.24M |
| Aug 21, 2026 | $10.22 | $10.48 | $10.055 | $10.25 | 1.02M |
| Aug 20, 2026 | $10.48 | $10.635 | $10.15 | $10.18 | 1.14M |
| Aug 19, 2026 | $10.80 | $11.03 | $10.49 | $10.58 | 1.55M |
Latest SGMT news
The latest Smart Investors Daily articles mentioning SGMT.
Stock researchCompany · Overview
SGMT research
Overview
Company profile and research snapshot.
Company profile
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $6.00
- Implied upside
- —
- Analysts
- 16
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 9, 2026 | Barclays | Overweight | — |
| Sep 9, 2026 | Cantor Fitzgerald | Overweight | — |
| Aug 25, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 14, 2026 | Citizens | Market Outperform | — |
| Aug 12, 2026 | Canaccord Genuity | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Sep 9, 2026
Barclays Upgrades Sagimet Biosciences to Overweight, Raises Price Target to $18
Barclays analyst Eliana Merle upgrades Sagimet Biosciences (NASDAQ:SGMT) from Equal-Weight to Overweight and raises the price target from $8 to $18.
Benzinga · Sep 9, 2026
Cantor Fitzgerald Initiates Coverage On Sagimet Biosciences with Overweight Rating, Announces Price Target of $10.71
Cantor Fitzgerald analyst Yanni Souroutzidis initiates coverage on Sagimet Biosciences (NASDAQ:SGMT) with a Overweight rating and announces Price Target of $10.71.
Yahoo · Sep 2, 2026
Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences
FOSTER CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in two upcoming investor conferences. Cantor 2026 Global Healthcare Conference in New York, NY on Wednesday, September 9, 2026, with a fireside chat at 1.35pm ET (link here).H.C. Wainwright 28th Annual Global Investment Conf
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
